UCB Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in Patients with Moderate-to-Severe Plaque Psoriasis.

Brussels, Belgium – April 27, 6:00 PM CEST – UCB today announced that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for CIMZIA® (certolizumab pegol), to include a new indication in adult patients with moderate-to-severe plaque psoriasis.3 CIMZIA is the first Fc-free, PEGylated anti-TNF to receive a positive CHMP opinion for use in moderate-to-severe plaque psoriasis.3 The European Commission’s (EC) endorsement of the CHMP positive opinion for psoriasis is expected in the second quarter of 2018 and would further broaden the...